Global Alzheimer’s Initiative Now Act

[Congressional Bills 119th Congress]
[From the U.S. Government Publishing Office]
[H.R. 3674 Introduced in House (IH)]

<DOC>

119th CONGRESS
  1st Session
                                H. R. 3674

   To authorize United States participation in the Davos Alzheimer's
                             Collaborative.

_______________________________________________________________________

                    IN THE HOUSE OF REPRESENTATIVES

                              June 3, 2025

 Mr. Bera (for himself, Mr. Fitzpatrick, and Mrs. Kim) introduced the
 following bill; which was referred to the Committee on Foreign Affairs

_______________________________________________________________________

                                 A BILL

   To authorize United States participation in the Davos Alzheimer's
                             Collaborative.

    Be it enacted by the Senate and House of Representatives of the
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Global Alzheimer's Initiative Now
Act''.

SEC. 2. FINDINGS.

    Congress finds the following:
            (1) Alzheimer's disease and dementia currently afflicts
        nearly 60 million people across the globe, a number that is
        projected to jump to more than 150 million by 2050.
            (2) There are now more global cases of Alzheimer's disease
        and dementia than cancer and HIV combined, with 39 million
        diagnosed cases of HIV/AIDS and 20 million cases of cancer in
        2022.
            (3) The pace of populations aging will challenge countries'
        sovereign funds and health and social safety systems.
            (4) By 2050, the world's population of people aged 60 years
        and older will double to 1.6 billion and reach a proportion of
        22 percent of the world's population. While the number of
        persons aged 80 or older is expected to triple by 2050.
            (5) The old-age dependency ratio, expressing the relative
        size of the older population compared with the working-age
        population, is projected to more than double by 2075 in the
        majority of the world. Rising dependency ratios will result in
        increasing pressures on old-age support systems, with fewer
        people of working age for each older person.
            (6) The prevalence of Alzheimer's disease and dementia is
        growing most rapidly in low- and middle-income countries, which
        comprise more than 70 percent of the world's Alzheimer's
        disease and dementia cases.
            (7) Every year, Alzheimer's disease and dementia costs the
        global economy more than $1.3 trillion and this is doubling
        every decade.
            (8) By 2050, the number of Americans living with
        Alzheimer's disease and dementia is expected to reach 12.7
        million, bringing the total cost to nearly $1 trillion each
        year, with minority populations in the United States
        disproportionately impacted by these trends.
            (9) International Alzheimer's research across all races and
        ethnicities directly benefits minority populations in the
        United States.
            (10) Women are disproportionately affected by Alzheimer's
        disease and dementia, both directly and indirectly. Women
        experience higher disability-adjusted life years and mortality
        due to Alzheimer's disease and dementia, but also provide 70
        percent of care hours for people living with Alzheimer's
        disease and dementia.
            (11) The Davos Alzheimer's Collaborative (DAC) is a public-
        private-patient venture, launched in 2021, that is transforming
        Alzheimer's disease and dementia research, prevention, and care
        in low-income, middle-income, and high-income settings
        globally.
            (12) DAC seeks to raise and deploy over $700 million over 6
        years to accelerate innovation in drug development and
        transform the way healthcare systems prevent, diagnose, and
        treat Alzheimer's disease and dementia for all people in all
        places.
            (13) In 2023, DAC supported 19 healthcare systems in 12
        countries, including the United States.
            (14) The United States Government has traditionally been
        the largest funder of global health programs, with
        approximately $12 billion in funding in fiscal year 2024 for
        programs that cover the full range of global health challenges.
            (15) The United States Government has been a lead funder of
        multilateral health initiatives, such as Gavi, the Vaccine
        Alliance, the Global Fund to Fight AIDS, TB and Malaria, the
        Coalition for Epidemic Preparedness Innovations, and the
        International AIDS Vaccine Initiative.

SEC. 3. STATEMENT OF POLICY.

    It shall be the policy of the United States--
            (1) to lead global cooperative efforts to combat
        Alzheimer's disease and dementia, including in countries with
        low-income economies and countries with middle-income economies
        (as such terms are defined by the World Bank) that represent
        the majority of future cases; and
            (2) to lead multilateral health initiatives, including the
        Davos Alzheimer's Collaborative--
                    (A) to develop diagnostics and treatments for
                diverse populations in the United States and across the
                globe;
                    (B) to promote international development
                cooperation; and
                    (C) to provide substantial leverage and burden
                sharing for United States investments.

SEC. 4. AUTHORIZATION FOR UNITED STATES PARTICIPATION IN THE DAVOS
              ALZHEIMER'S COLLABORATIVE.

    (a) In General.--The United States is hereby authorized to
participate in, and contribute to, the Davos Alzheimer's Collaborative
(DAC) in order to advance international efforts to prevent, diagnose,
and treat Alzheimer's disease and dementia.
    (b) Designee.--
            (1) In general.--The President is authorized to designate
        an employee of the relevant Federal department or agency
        providing the majority of United States contributions to DAC to
        serve on the Advisory Council of DAC and, if nominated, on the
        Board of Directors of DAC, as a representative of the United
        States.
            (2) Qualifications.--The individual to be designated
        pursuant to paragraph (1) should demonstrate knowledge and
        experience in the fields of development and public health.
            (3) Cooperation.--In carrying out this section, the
        individual designated pursuant to paragraph (1) shall
        coordinate with the USAID Administrator, the Secretary of
        State, and the Secretary of Health and Human Services to
        promote alignment, as appropriate, between DAC and United
        States global health and Alzheimer's disease and dementia
        research and development programs.
    (c) United States Contributions.--
            (1) In general.--Amounts authorized to be appropriated and
        made available to carry out chapters 1 and 10 of part I and
        chapter 4 of part II of the Foreign Assistance Act of 1961 (22
        U.S.C. 2151 et seq.) are authorized to be made available for
        United States contributions to DAC.
            (2) Matching requirement.--Amounts made available under
        paragraph (1) may be obligated and expended only to the extent
        that DAC secures funding from sources other than the United
        States. At any time during fiscal years 2026 through 2030, no
        United States contribution to DAC may cause the total amount of
        United States Government contributions to DAC to exceed 33
        percent of the total amount of funds contributed to the DAC
        from all sources.
    (d) Report.--Not later than 180 days after the date of the
enactment of this Act, and on an annual basis thereafter, the President
shall submit to the appropriate congressional committees a report that
includes the following:
            (1) A description of any planned financial contributions
        from the United States Government to DAC.
            (2) The manner and extent to which the United States will
        participate in the governance of DAC.
            (3) A summary of private and governmental contributions to
        DAC.
            (4) A description of how participation in DAC supports
        relevant United States Government strategies and programs to
        combat Alzheimer's disease and dementia and to promote global
        health.
    (e) Definition.--In subsection (d), the term ``appropriate
congressional committees'' means--
            (1) the Committee on Foreign Affairs and Committee on
        Appropriations of the House of Representatives; and
            (2) the Committee on Foreign Relations and the Committee on
        Appropriations of the Senate.
                                 <all>